4.7 Review

Strength in numbers: antifungal strategies against fungal biofilms

期刊

出版社

ELSEVIER
DOI: 10.1016/j.ijantimicag.2013.10.023

关键词

Candida; Biofilm; Antifungal; Echinocandin; Liposomal amphotericin B

资金

  1. BBSRC
  2. Wellcome Trust
  3. GSK
  4. Gilead Sciences
  5. Technology Strategy Board
  6. Fulhold

向作者/读者索取更多资源

Pathogenic fungi have the capacity to form tenacious biofilm structures that are notoriously unresponsive to antifungal therapies. Fungal biofilms are ubiquitous, located all over the human host, including the oral cavity, respiratory tract, gastrointestinal tract, urinary tract, wounds and upon biomedical devices. This latter category represents one of the greatest hurdles in clinical management, where the presence of inert substrates such as a catheter provides a reservoir for fungal biofilm development. Here, Candida albicans is the most adept at forming biofilms and is the principal nosocomial fungal pathogen based on its high rates of mortality, which are often associated with the biofilm lifestyle. This review will summarise some of the key fungal biofilm-forming organisms and their clinical significance and will discuss current and novel strategies to manage these hard-to-treat infections based on in vitro and in vivo studies. (C) 2013 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据